

# Product datasheet for SR313204

## PARP9 Human siRNA Oligo Duplex (Locus ID 83666)

## **Product data:**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	siRNA Oligo Duplexes
Purity:	HPLC purified
Quality Control:	Tested by ESI-MS
Sequences:	Available with shipment
Stability:	One year from date of shipment when stored at -20°C.
# of transfections:	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note:	Single siRNA duplex (10nmol) can be ordered.
RefSeq:	<u>NM_001146102, NM_001146103, NM_001146104, NM_001146105, NM_001146106, NM_031458</u>
UniProt ID:	<u>Q8IXQ6</u>
Synonyms:	ARTD9; BAL; BAL1; MGC:7868
Components:	PARP9 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 83666) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

#### **GRIGENE** PARP9 Human siRNA Oligo Duplex (Locus ID 83666) – SR313204

ADP-ribosyltransferase which, in association with E3 ligase DTX3L, plays a role in DNA Summary: damage repair and in immune responses including interferon-mediated antiviral defenses (PubMed:16809771, PubMed:23230272, PubMed:26479788, PubMed:27796300). Within the complex, enhances DTX3L E3 ligase activity which is further enhanced by PARP9 binding to poly(ADP-ribose) (PubMed:28525742). In association with DTX3L and in presence of E1 and E2 enzymes, mediates NAD(+)-dependent mono-ADP-ribosylation of ubiquitin which prevents ubiquitin conjugation to substrates such as histones (PubMed:28525742). During DNA repair, PARP1 recruits PARP9/BAL1-DTX3L complex to DNA damage sites via PARP9 binding to ribosylated PARP1 (PubMed:23230272). Subsequent PARP1-dependent PARP9/BAL1-DTX3Lmediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed:23230272, PubMed:28525742). In response to DNA damage, PARP9-DTX3L complex is required for efficient non-homologous end joining (NHEJ); the complex function is negatively modulated by PARP9 activity (PubMed:28525742). Dispensable for B-cell receptor (BCR) assembly through V(D) recombination and class switch recombination (CSR) (By similarity). In macrophages, positively regulates pro-inflammatory cytokines production in response to IFNG stimulation by suppressing PARP14-mediated STAT1 ADP-ribosylation and thus promoting STAT1 phosphorylation (PubMed:27796300). Also suppresses PARP14-mediated STAT6 ADPribosylation (PubMed:27796300).[UniProtKB/Swiss-Prot Function]

PerformanceOriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit willGuaranteed:provide at least 70% or more knockdown of the target mRNA when used at 10 nMconcentration by quantitative RT-PCR when the TYE-563 fluorescent transfection controlduplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRTpositive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US